Physician profile
Darryn Potosky
NPI 1538384862
$71,867.06
in general payments reported to CMS, 2019-2025
16 companies · $21K in 2025
The $21K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,954 · 2020: $14K · 2021: $3,535 · 2022: $4,288 · 2023: $14K · 2024: $8,206 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $14K · Food and Beverage: $1,515 · Travel and Lodging: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,854.50 |
| Consulting Fee | $14,282.50 |
| Food and Beverage | $1,514.76 |
| Travel and Lodging | $822.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $41,999.40 | 2019-2025 | Fibroscan, Fibroscan |
| Madrigal Pharmaceuticals | $24,863.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $2,640.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $1,550.52 | 2025 | Iqirvo |
| Fujifilm Healthcare Americas Corporation | $241.65 | 2022-2024 | Fujifilm |
| Abbvie INC. | $174.40 | 2022-2025 | |
| Gilead Sciences, INC. | $122.68 | 2019-2025 | |
| Genzyme Corporation | $77.31 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.80 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $33.09 | 2023 | Remicade, Simponi, Stelara |
| Kadmon Pharmaceuticals LLC | $24.97 | 2020 | |
| Braintree Laboratories, INC. | $19.98 | 2023 | Suflave, Sutab |
| Shionogi INC | $19.17 | 2019 | |
| Orphalan INC | $18.61 | 2025 | Cuvrior |
| Alnylam Pharmaceuticals INC. | $16.53 | 2024 | Givlaari |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryn Potosky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.